Daiwa Securities Group
VOR icon

Daiwa Securities Group’s Vor Biopharma VOR Stock Holding History

Daiwa Securities Group’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5
Closed – – 1393
2022
Q3 		$0 Hold
5
– – ﹤0.01% 1403
2022
Q2 		$1K Hold
5
– – ﹤0.01% 1327
2022
Q1 		$1K Hold
5
– – ﹤0.01% 1346
2021
Q4 		$1K Buy
+5
New +$1.44K ﹤0.01% 1365

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Daiwa Securities Group's VOR Position: Q4 2022 in Review

Daiwa Securities Group sold out of Vor Biopharma (VOR) in Q4 2022, closing a stake of 5 shares.

Daiwa Securities Group first reported a position in VOR in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q2 2022. 58 funds tracked by Wall St. Rank hold VOR as of Q4 2022.

  • Daiwa Securities Group reported no remaining Vor Biopharma position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 5 Vor Biopharma shares in Q4 2022.
  • Daiwa Securities Group first reported a position in Vor Biopharma in Q4 2021 and held it in 4 quarters.
  • Daiwa Securities Group's Vor Biopharma position peaked at $1K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.